Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Results on August 12, 2025
Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, has scheduled its Q2 2025 financial results announcement for August 12, 2025.
The company will release results before market open, followed by a management-hosted webcast conference call at 8:30 a.m. ET on the same day. The webcast will be available on the company's website and archived for future reference.
Rapid Micro Biosystems (NASDAQ: RPID), un'azienda tecnologica nel settore delle scienze della vita specializzata in soluzioni di automazione per la produzione di prodotti sanitari, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 12 agosto 2025.
L'azienda pubblicherà i risultati prima dell'apertura del mercato, seguiti da una conference call con webcast condotta dal management alle 8:30 ET dello stesso giorno. Il webcast sarà disponibile sul sito web dell'azienda e archiviato per consultazioni future.
Rapid Micro Biosystems (NASDAQ: RPID), una empresa de tecnología en ciencias de la vida especializada en soluciones de automatización para la fabricación de productos sanitarios, ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el 12 de agosto de 2025.
La compañía publicará los resultados antes de la apertura del mercado, seguido de una llamada conferencia con webcast presentada por la dirección a las 8:30 a.m. ET del mismo día. El webcast estará disponible en el sitio web de la empresa y se archivará para futuras consultas.
Rapid Micro Biosystems (NASDAQ: RPID)는 의료 제품 제조 자동화 솔루션을 전문으로 하는 생명 과학 기술 회사로, 2025년 8월 12일에 2025년 2분기 재무 결과 발표를 예정하고 있습니다.
회사는 시장 개장 전 결과를 발표하며, 같은 날 동부 표준시 오전 8:30에 경영진 주최 웹캐스트 컨퍼런스 콜이 진행됩니다. 웹캐스트는 회사 웹사이트에서 시청 가능하며, 이후 참고를 위해 아카이브됩니다.
Rapid Micro Biosystems (NASDAQ : RPID), une entreprise technologique spécialisée dans les sciences de la vie et les solutions d'automatisation pour la fabrication de produits de santé, a programmé l'annonce des résultats financiers du deuxième trimestre 2025 pour le 12 août 2025.
La société publiera les résultats avant l'ouverture des marchés, suivie d'une conférence téléphonique en webcast animée par la direction à 8h30 ET le même jour. Le webcast sera accessible sur le site web de l'entreprise et archivé pour consultation ultérieure.
Rapid Micro Biosystems (NASDAQ: RPID), ein Life-Sciences-Technologieunternehmen, das sich auf Automatisierungslösungen für die Herstellung von Gesundheitsprodukten spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 12. August 2025 geplant.
Das Unternehmen wird die Ergebnisse vor Markteröffnung veröffentlichen, gefolgt von einem von der Geschäftsführung geleiteten Webcast-Konferenzgespräch um 8:30 Uhr ET am selben Tag. Der Webcast wird auf der Unternehmenswebsite verfügbar sein und für zukünftige Referenzen archiviert.
- None.
- None.
LEXINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2025 financial results prior to the market open on Tuesday, August 12, 2025.
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Tuesday, August 12, 2025. The live audio webcast will be accessible on the Company’s website and can be accessed with this link. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
FAQ
When will Rapid Micro Biosystems (RPID) release Q2 2025 earnings?
What time is the RPID Q2 2025 earnings conference call?
How can investors access Rapid Micro Biosystems Q2 2025 earnings call?
What does Rapid Micro Biosystems (RPID) do?
